Timothy M. Ullmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timothy M. Ullmann has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Thomas J. Fahey
Department of Surgery, Weill Cornell Medical Center, New York, USA
13 shared publications - Irene M. Min
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
12 shared publications - Rasa Zarnegar
Department of Surgery, Weill Cornell Medicine , New York, NY 10065
12 shared publications - Caitlin E. Egan
Department of Surgery, Weill Cornell Medicine, New York, New York
11 shared publications - Dessislava Stefanova
Weill Cornell Medicine 3 Department of Surgery New York, New York
11 shared publications - Hala Al Asadi
Department of Surgery, Division of Endocrine & Minimally Invasive Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, USA
11 shared publications
Latest Publications
- 29 October 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 328, 278-283
Growth of Benign Thyroid Nodules Is Associated With a High Reintervention Rate Without Clear Benefit
- 29 October 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 328, 278-283
Growth of Benign Thyroid Nodules Is Associated With a High Reintervention Rate Without Clear Benefit
- 1 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11038
ASO Visual Abstract: Disparities in Active Surveillance of Papillary Thyroid Microcarcinomas
- 1 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11038
ASO Visual Abstract: Disparities in Active Surveillance of Papillary Thyroid Microcarcinomas
- 26 August 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11027-11033
Disparities in Active Surveillance of Papillary Thyroid Microcarcinomas
- 26 August 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 11027-11033
Disparities in Active Surveillance of Papillary Thyroid Microcarcinomas
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.
- Open Access
- 26 February 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (5) , 3119-3125
The Landmark Series: Extent of Surgery for Low-Risk Differentiated Thyroid Cancer
The management of patients with differentiated thyroid cancers (DTCs) at low risk for disease progression or relapse after treatment remains controversial. These patients have excellent disease-specific survival. Therefore, minimizing the impact of treatments on patients’ quality of life is particularly important. For these reasons, the pendulum has swung in recent years to favor less extensive surgery toward lobectomy instead of total thyroidectomy, away from prophylactic (central compartment) lymphadenectomy, and even in some cases, omitting surgery altogether. This review discusses several of the influential studies from the past two decades that have had an impact on the management for these patients, including a shift toward more personalized care.
- 26 February 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (5) , 3119-3125
Open AccessThe Landmark Series: Extent of Surgery for Low-Risk Differentiated Thyroid Cancer
The management of patients with differentiated thyroid cancers (DTCs) at low risk for disease progression or relapse after treatment remains controversial. These patients have excellent disease-specific survival. Therefore, minimizing the impact of treatments on patients’ quality of life is particularly important. For these reasons, the pendulum has swung in recent years to favor less extensive surgery toward lobectomy instead of total thyroidectomy, away from prophylactic (central compartment) lymphadenectomy, and even in some cases, omitting surgery altogether. This review discusses several of the influential studies from the past two decades that have had an impact on the management for these patients, including a shift toward more personalized care.
- 12 September 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 81 (11) , 1602-1611
Impact of Holistic Application Scoring on Interview Offers
- 12 September 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 81 (11) , 1602-1611
Impact of Holistic Application Scoring on Interview Offers
- 3 September 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 81 (11) , 1553-1557
Bias Perpetuates Bias: ChatGPT Learns Gender Inequities in Academic Surgery Promotions
- 3 September 2024
- Published by Elsevier in Journal of Surgical Education
- Vol. 81 (11) , 1553-1557
Bias Perpetuates Bias: ChatGPT Learns Gender Inequities in Academic Surgery Promotions
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.